RxDoctor Payments Data

Dorothy Jackson, MD

Family Medicine · Tyler, TXNPI 1922071042

Payments from drug & device makers

$2,537in general payments, 2019–2025

Across 156 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$547
  • Merck$449
  • Lilly USA, LLC$397
  • Sanofi-aventis U.S. LLC$296
  • Boehringer Ingelheim$173
  • AstraZeneca$168
  • plus $508 from 12 others

What the payments were for

  • Food & beverage$2,526100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,537 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$30,583
Medicare patients
53
Services billed
399

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide124$151,307
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog45$64,133
JardianceEmpagliflozin38$40,235
MounjaroTirzepatide29$34,720
Janumet XrSitagliptin Phos/Metformin Hcl41$28,788
EliquisApixaban15$17,357
TradjentaLinagliptin16$13,228
XareltoRivaroxaban14$12,363
ZubsolvBuprenorphine Hcl/Naloxone Hcl12$5,297
Lurasidone Hcl13$4,957
SymbicortBudesonide/Formoterol Fumarate18$4,631
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$2,824
Albuterol Sulfate HfaAlbuterol Sulfate83$2,705
Atorvastatin Calcium288$2,646
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl12$2,278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$547$151,307124 claims
Boehringer IngelheimJardiance, Tradjenta$173$53,46354 claims
Lilly USA, LLCMounjaro$397$34,72029 claims
MerckJanumet Xr$449$28,78841 claims
PfizerEliquis$71$17,35715 claims
AstraZenecaSymbicort$168$4,63118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →